Faites glisser pour repositionner la couverture
Sur
At LIQOMICS, we specialize in advanced minimal residual disease (MRD) testing using liquid biopsy techniques. Our ctDNA-based assays offer unparalleled sensitivity, enabling early detection of residual cancer cells post-treatment. This approach facilitates timely interventions and personalized treatment strategies. Trust LIQOMICS for precise MRD monitoring to enhance patient outcomes.
Recadrez votre avatar
